Revvity, Inc. (RVTY) Earnings Call Transcripts

Revvity, Inc.'s Latest Earnings Call - June 9, 2026

In the first quarter of fiscal year 2026, Revvity, Inc. reported solid growth driven by its Diagnostics and Life Sciences segments. Revenue reached $X million, with earnings per share (EPS) of $Y, reflecting a strong performance amid ongoing market challenges. Management provided a pro forma organic revenue growth guidance of 3% to 4% for the full year, indicating a conservative outlook for the second half, which could impact investor sentiment.

Reported metrics

Guidance from management

Management maintained a conservative guidance for the full year, projecting pro forma organic revenue growth of 3% to 4%. They indicated no expected ramp-up in growth for the second half, which may concern investors.

What management said

Yes. Just as we look at the businesses, as you said, we had a great start to the year. On the Diagnostics side, reproductive health franchise continues to do very well. Immunodiagnostic to ex China was performing well across other geographies. On the Life Sciences side, [indiscernible] planned single, our reagents business grew low single coming back, as we've said now for a couple of quarters, academia and research ...

Yes. I mean, again, as we mentioned during the earnings call, this is -- and we expect to close on this towards the end of 2027. And as you said, it was a drag both on growth and on cash flow. So we don't expect to have a huge cash influx coming in from the acquisition -- from the divestiture, but we would typically use it whatever comes in for typically the share buybacks, which is probably our primary target right ...

What analysts pressed on

Analysts expressed concerns regarding the conservative guidance and the potential impact of the divestiture on cash flow. There were also questions about the sustainability of growth in the U.S. immunodiagnostics market, particularly related to latent tuberculosis testing.

Main topics on the call

• Revenue Growth in Diagnostics — Revvity's Diagnostics segment saw strong performance, particularly in reproductive health, which grew low double digits. CEO Prahlad Singh noted, "the reproductive health business has done much better than what we have h...
• Divestiture of China Immunodiagnostics Business — The planned divestiture of the China immunodiagnostics business is expected to close by the end of 2027. Singh stated, "it was a drag both on growth and on cash flow," suggesting that this move could help improve overall...
• Geographic Expansion Success — Management highlighted successful geographic expansion, particularly in markets like the U.K. and France, where new bond screening programs are being adopted. Singh mentioned, "we are starting to see adoption of newborn ...
• Conservative Guidance for Future Growth — Management's guidance for the second half of the year reflects a conservative outlook, with no expected ramp-up in growth. Singh noted, "we feel very comfortable and optimistic about the way we've guided for the year," b...

Read the full Revvity, Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 89 Revvity, Inc. earnings call transcripts on record, spanning January 14, 2020 to June 9, 2026. Based on this history, Revvity, Inc. reports quarterly. The most recent call on file is dated June 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

RVTY

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Life Sciences Tools and Services

Calls on record

89

First call

January 14, 2020

Most recent

June 9, 2026

Reporting cadence

quarterly